此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The MedMemos Study: Promoting Adherence to Medications in Pediatric Bone Marrow Transplant Patients (MedMemos)

2026年7月17日 更新者:Ahna Pai、Nationwide Children's Hospital

MedMemos: An Intervention to Promote Medication Adherence in Pediatric Allogenic Hematopoietic Stem Cell Transplantation

The goal of this clinical trial is to test the MedMemos Intervention with parents and children who have received a bone marrow transplant. The main study questions are:

  • Is the MedMemos intervention acceptable to patients and families?
  • Is the MedMemos intervention feasible for patients, families, and healthcare providers?
  • Does MedMemos help patients and families take their medications better?

Participants will be asked to complete surveys, attend 4 intervention sessions, and use an electronic box or pill bottle to store their medications in.

研究概览

地位

招聘中

详细说明

This study will assess the acceptability, feasibility, and proof-of-concept for MedMemos, a novel medication adherence promotion intervention developed for caregivers of children who received a pediatric hematopoietic stem cell transplant (PAHCT).

研究类型

介入性

注册 (估计的)

25

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子

接受健康志愿者

不

描述

Inclusion Criteria:

  • Child had a Pediatric Allogeneic Hematopoietic Cell Transplant (PAHCT)
  • Child is 0-12 years of age
  • At the time of recruitment child is still in the hospital for PAHCT
  • Child's primary caregiver is responsible for administering medical care and is willing to give consent to participate
  • Child is prescribed an oral medication regimen at discharge

Exclusion Criteria:

  • Caregiver does not speak English, Spanish, or Arabic
  • Caregiver is not available to provide written permission for the child's participation
  • EMR or medical team report of the caregiver's cognitive status precludes completion of questionnaires
  • The child's medical status or condition precludes completion of the study questionnaires as determined by the physician or caregiver
  • Caregiver is unwilling to store medication in an electronic monitor

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:MedMemos
This arm will provide participants with the MedMemos Intervention
MedMemos is a 4-session tailored adherence promotion intervention that will provide caregivers with a combination of tailored and standardized medication and adherence education videos and a "Medication Management Kit" that provides tailored strategies to target identified barriers to successful medication management.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Intervention Acceptability
大体时间:At the end of session 4 (An average of 14 days following the patient's hospital discharge, up to 28 days following discharge)
Intervention acceptability will be demonstrated by caregivers rating MedMemos a mean of ≥ 4 as measured on Acceptability of Intervention Measure, Feasibility of Intervention Measure, and Intervention Appropriateness Measure. Each measure asks participants to rate statements on a scale of "Completely Disagree" to "Completely Agree" Higher scores indicate greater acceptability, feasibility, and appropriateness.
At the end of session 4 (An average of 14 days following the patient's hospital discharge, up to 28 days following discharge)
Intervention Feasibility - Percentage of patients who enroll out of those approached
大体时间:Enrollment rate will be continually monitored throughout enrollment and final enrollment percentage will be calculated at the close of enrollment. Enrollment is estimated to end during Month 9 of Year 2.
Feasibility will be assessed by calculating enrollment rate (total number of patients enrolled / total number of patients approached). Feasible enrollment will be achieved by enrolling 80% or more of eligible caregivers.
Enrollment rate will be continually monitored throughout enrollment and final enrollment percentage will be calculated at the close of enrollment. Enrollment is estimated to end during Month 9 of Year 2.
Intervention Feasibility - Percentage of intervention sessions and follow-ups completed by enrolled participants.
大体时间:Completion rates will be calculated during the study in real time as part of study monitoring. Final study completion rates will be reported after the final follow-up is complete. Follow-ups are estimated to be complete Month 11 of Year 2.
Feasibility will be assessed by calculating the percentage of MedMemos sessions attended and the number of follow-up visits completed. Feasibility will be achieved if 80% or more of MedMemos sessions are attended by participants and if 80% or more of follow-up visits are completed by participants.
Completion rates will be calculated during the study in real time as part of study monitoring. Final study completion rates will be reported after the final follow-up is complete. Follow-ups are estimated to be complete Month 11 of Year 2.
Intervention Feasibility - Percentage of the intervention protocol delivered by the interventionist.
大体时间:Intervention fidelity will be monitored in real time to maintain adherence to the intervention protocol. Final intervention fidelity will be reported after the final MedMemos session is completed. Sessions are anticipated to end in Month 11 Year 2.
Feasibility of the intervention delivery will be assessed by calculating the intervention fidelity. Fidelity will be assessed by a member of the lab not involved in intervention delivery using a fidelity checklist developed by the study Principal Investigator. Feasibility of the intervention delivery will be achieved if fidelity checklist scores are 80% are greater (80% or more of the intervention delivered across the study)
Intervention fidelity will be monitored in real time to maintain adherence to the intervention protocol. Final intervention fidelity will be reported after the final MedMemos session is completed. Sessions are anticipated to end in Month 11 Year 2.

次要结果测量

结果测量
措施说明
大体时间
Adherence to immunosuppressant medication as assessed by electronic monitor
大体时间:Daily adherence will be monitored for each patient after discharge through the 3-month follow-up.
To establish proof-of-concept adherence to immunosuppressants will be monitored for all patients. Proof-of-concept will be established if ≥75% children take ≥75% of their immunosuppressant medication doses at all follow-up time points as measured by electronic monitor.
Daily adherence will be monitored for each patient after discharge through the 3-month follow-up.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月1日

初级完成 (估计的)

2028年12月31日

研究完成 (估计的)

2028年12月31日

研究注册日期

首次提交

2026年4月9日

首先提交符合 QC 标准的

2026年7月17日

首次发布 (实际的)

2026年7月21日

研究记录更新

最后更新发布 (实际的)

2026年7月21日

上次提交的符合 QC 标准的更新

2026年7月17日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

This is a rare treatment that treats even rarer diseases. Although identifiers will be removed from the final dataset, it will still include variables such as diagnosis treated by PAHCT, cell source for transplant (e.g., bone marrow, cord blood), date of transplant, and age at transplant that are frequently important to include in analyses. Given the rarity of this treatment, the investigators believe there remains the possibility of deductive disclosure of participants with uncommon characteristics (e.g., rare cancer diagnosis). To protect the rights and privacy of human subjects the investigators will not be sharing IPD, but instead will share de-identified aggregated qualitative data via the Cancer Data Service (CDS) database.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅